Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine is a Conjugate Vaccine owned by GSK, and is involved in 62 clinical trials, of which 58 were completed, and 4 are ongoing.

Neisseria meningitidis is a gram-negative diplococcus which causes meningitis and sepsis. Globally, 5 serogroups, A, B, C, Y and W-135 cause almost all invasive meningococcal infections. The presence of serum bactericidal antibodies protects against invasive meningococcal disease. Vaccination with menveo leads to the production of bactericidal antibodies directed against the capsular polysaccharides of serogroups A, C, Y and W-135.

The revenue for Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine is expected to reach a total of $5.9bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine NPV Report.

Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine was originated by Novartis and is currently owned by GSK. CanSino Biologics is the other company associated in development or marketing of Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine.

Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine Overview

Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine) (Menveo / Menivact / Menhycia) is a sterile liquid vaccine. It is formulated as lyophilized powder for injection and injection solution for intramuscular route of administration. It is indicated for active immunization to prevent meningococcal disease caused by neisseria meningitidis serogroups. It is also approved for the prevention of meningococcal disease caused by four strains of the bacterium Neisseria meningitidis (N. meningitidis) in infants and toddlers from 2 months of age. It is quadrivalent vaccine acts by producing bactericidal antibodies.

It is under development for the prevention of Neisseria meningitidis infections. It is also indicated for active immunization of infants (from two months of age) and children to prevent invasive disease caused by the bacteria Neisseria meningitidis serogroups A, C, W135 and Y1. The vaccine can also be used in adolescents and adults to help protect against the four strains of meningococcal disease contained in the vaccine.

GSK Overview

GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.

The company reported revenues of (British Pounds) GBP34,114 million for the fiscal year ended December 2021 (FY2021), an increase of 0% over FY2020. In FY2021, the company’s operating margin was 18.1%, compared to an operating margin of 22.8% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 16.9% in FY2020. The company reported revenues of GBP7,829 million for the third quarter ended September 2022, an increase of 13% over the previous quarter.

Quick View – Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine

Report Segments
  • Innovator (NME)
Drug Name
  • Meningococcal polysaccharide [serotypes A, C, W-135, Y] vaccine
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.